

ANTIBODY DRUGS: TECHNOLOGIES AND GLOBAL MARKETS



BIO016J
January 2015

Shalini Shahani Dewan
Project Analyst

ISBN: 1-62296-009-2



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	3
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR ANTIBODY DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL MARKET FOR ANTIBODY DRUGS BY REGION, 2012-2019 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
DEFINITIONS	10
MONOCLONAL ANTIBODIES	10
HISTORY OF MONOCLONAL ANTIBODIES	11
<i>TABLE 1 EVOLUTION OF MONOCLONAL ANTIBODIES</i>	11
<i>TABLE 2 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES</i>	12
<i>TABLE 3 DIFFERENCES BETWEEN MONOCLONAL ANTIBODY DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS</i>	12
TYPES OF MONOCLONAL ANTIBODIES	13
Murine Monoclonal Antibodies	13
<i>TABLE 4 MURINE MONOCLONAL ANTIBODIES</i>	14
Chimeric Monoclonal Antibodies	14
<i>TABLE 5 CHIMERIC MONOCLONAL ANTIBODIES</i>	14
Humanized Monoclonal Antibodies	14
<i>TABLE 6 HUMANIZED MONOCLONAL ANTIBODIES</i>	15
Human Monoclonal Antibodies	15
<i>TABLE 7 HUMAN MONOCLONAL ANTIBODIES</i>	16
MANUFACTURING TECHNOLOGIES OF MONOCLONAL ANTIBODIES	16
Hybridoma Technology	16
Production of Recombinant Antibodies by Display Technology	17
<i>TABLE 8 DIFFERENCES BETWEEN HYBRIDOMA TECHNOLOGY AND RECOMBINANT TECHNOLOGY</i>	18
Production of Antibodies in Plants	18
Recombinant Antibody Expression in Transgenic Plants	18
Recombinant Antibody Expression in Transgenic Animals	19
Mammalian Cell Culture	19
Microbial Cell Fermentation	20

TOPIC	PAGE NO.
<i>TABLE 9 COMPARISON OF VARIOUS EXPRESSION SYSTEMS FOR RECOMBINANT PHARMACEUTICAL PROTEINS</i>	21
APPLICATIONS OF MONOCLONAL ANTIBODIES	21
Diagnostic Tests	21
Human Therapy	21
<i>TABLE 10 MURINE MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS</i>	22
<i>TABLE 11 CHIMERIC MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS</i>	22
<i>TABLE 12 HUMAN MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS</i>	23
<i>TABLE 13 HUMANIZED MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS</i>	23
CHAPTER 4 REGULATORY ASPECTS	26
<i>TABLE 14 NEW APPROVALS OF MONOCLONAL ANTIBODIES FROM JANUARY 2009 TO MAY 2014</i>	26
RECALLS	28
<i>TABLE 15 RECALLS FROM JANUARY 2009 TO JUNE 2014</i>	29
NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS	29
<i>TABLE 16 NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS FROM JANUARY 2009 TO JANUARY 2014</i>	30
SAFETY ALERTS	31
<i>TABLE 17 SAFETY ALERTS FROM 2010 TO MAY 2014</i>	31
CHAPTER 5 NEW DEVELOPMENTS	35
PHASE I CLINICAL TRIALS	35
<i>TABLE 18 MONOCLONAL ANTIBODIES IN PHASE I CLINICAL TRIALS</i>	35
PHASE II CLINICAL TRIALS	38
<i>TABLE 19 MONOCLONAL ANTIBODIES IN PHASE II CLINICAL TRIALS</i>	39
PHASE III CLINICAL TRIALS	42
<i>TABLE 20 MONOCLONAL ANTIBODIES IN PHASE III CLINICAL TRIALS</i>	43
PHASE IV CLINICAL TRIALS	44
<i>TABLE 21 MONOCLONAL ANTIBODIES IN PHASE IV CLINICAL TRIALS</i>	45
MERGERS AND ACQUISITIONS	45
<i>TABLE 22 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES FROM 2009 TO JUNE 2014</i>	46
CHAPTER 6 MARKET ANALYSIS OF ANTIBODY DRUGS	51
MARKET BY TYPE	51
MARKET OVERVIEW	52
MARKET REVENUE	54
<i>TABLE 23 GLOBAL REVENUE OF ANTIBODY DRUGS BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	54
<i>FIGURE 1 GLOBAL REVENUE OF ANTIBODY DRUGS BY TYPE, 2012-2019 (\$ MILLIONS)</i>	55
MARKET SHARE	55
<i>TABLE 24 MARKET SHARE OF ANTIBODY DRUGS BY TYPE, 2013 (%)</i>	55
<i>FIGURE 2 MARKET SHARE OF ANTIBODY DRUGS BY TYPE, 2013 (%)</i>	55
MARKET BY REGION	56
MARKET OVERVIEW	56
MARKET REVENUE	57

TOPIC	PAGE NO.
<i>TABLE 25 GLOBAL REVENUE OF ANTIBODY DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	58
<i>FIGURE 3 GLOBAL REVENUE OF ANTIBODY DRUGS BY REGION, 2012-2019 (\$ MILLIONS)</i>	58
MARKET SHARE	58
<i>TABLE 26 MARKET SHARE OF ANTIBODY DRUGS BY REGION, 2013 (%)</i>	59
<i>FIGURE 4 MARKET SHARE OF ANTIBODY DRUGS BY REGION, 2013 (%)</i>	59
Murine Monoclonal Antibodies	59
Market Overview	60
Market Revenue	60
<i>TABLE 27 GLOBAL REVENUE OF MURINE MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	61
<i>FIGURE 5 GLOBAL REVENUE OF MURINE MONOCLONAL ANTIBODIES BY REGION, 2012-2019 (\$ MILLIONS)</i>	61
Chimeric Monoclonal Antibodies	62
Market Overview	62
Market Revenue	63
<i>TABLE 28 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	63
<i>FIGURE 6 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY REGION, 2012-2019 (\$ MILLIONS)</i>	63
Human Monoclonal Antibodies	64
Market Overview	64
Market Revenue	65
<i>TABLE 29 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	66
<i>FIGURE 7 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY REGION, 2012-2019 (\$ MILLIONS)</i>	66
Humanized Monoclonal Antibodies	66
Market Overview	67
Market Revenue	67
<i>TABLE 30 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	68
<i>FIGURE 8 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY REGION, 2012-2019 (\$ MILLIONS)</i>	69
MARKET BY MANUFACTURING PROCESS	69
<i>TABLE 31 GLOBAL REVENUE OF MANUFACTURING PROCESSES BY TYPE OF MONOCLONAL ANTIBODIES, THROUGH 2019 (\$ MILLIONS)</i>	70
<i>FIGURE 9 GLOBAL REVENUE OF MANUFACTURING PROCESSES BY TYPE OF MONOCLONAL ANTIBODIES, 2012-2019 (\$ MILLIONS)</i>	70
MARKET SHARE	71
<i>TABLE 32 MARKET SHARE OF ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2013 (%)</i>	71
<i>FIGURE 10 MARKET SHARE OF ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2013 (%)</i>	71
Murine Monoclonal Antibodies	71
Market Overview	72
Market Revenue	72
<i>TABLE 33 GLOBAL REVENUE OF MURINE ANTIBODY DRUGS BY MANUFACTURING PROCESS, THROUGH 2019 (\$ MILLIONS)</i>	73

TOPIC	PAGE NO.
<i>FIGURE 11 GLOBAL REVENUE OF MURINE ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2012-2019 (\$ MILLIONS)</i>	73
Chimeric Monoclonal Antibodies	73
Market Overview	74
Market Revenue	75
<i>TABLE 34 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019 (\$ MILLIONS)</i>	75
<i>FIGURE 12 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019 (\$ MILLIONS)</i>	75
Human Monoclonal Antibodies	76
Market Overview	76
Market Revenue	77
<i>TABLE 35 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019 (\$ MILLIONS)</i>	77
<i>FIGURE 13 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019 (\$ MILLIONS)</i>	77
Humanized Monoclonal Antibodies	78
Market Overview	78
Market Revenue	79
<i>TABLE 36 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019 (\$ MILLIONS)</i>	79
<i>FIGURE 14 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019 (\$ MILLIONS)</i>	79
CHAPTER 7 MARKET APPLICATIONS OF ANTIBODY DRUGS	82
MARKET BY DISEASES	82
GLOBAL ANTIBODY DRUG MARKET BY DISEASES	82
<i>TABLE 37 GLOBAL REVENUE FOR ANTIBODY DRUGS BY DISEASES, THROUGH 2019 (\$ MILLIONS)</i>	83
<i>FIGURE 15 GLOBAL REVENUE FOR ANTIBODY DRUGS BY DISEASES, 2012-2019 (\$ MILLIONS)</i>	83
MARKET SHARE	83
<i>TABLE 38 MARKET SHARES FOR ANTIBODY DRUGS BY DISEASES, 2013 (%)</i>	84
<i>FIGURE 16 MARKET SHARE FOR ANTIBODY DRUGS BY DISEASES, 2013 (%)</i>	84
AUTOIMMUNE DISEASE	84
<i>TABLE 39 VARIOUS TYPES OF AUTOIMMUNE DISEASES</i>	85
Autoimmune Diseases by Type of Antibody Used	87
Market Overview	87
Market Revenue	87
<i>TABLE 40 GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	88
<i>FIGURE 17 GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY TYPE, 2012-2019 (\$ MILLIONS)</i>	88
Market Analysis of Autoimmune Diseases by Region	89
Market Overview	89
Market Revenue	90
<i>TABLE 41 GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	90
<i>FIGURE 18 GLOBAL MARKET FOR ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY REGION, 2012-2019 (\$ MILLIONS)</i>	90

TOPIC	PAGE NO.
SOLID TUMORS	91
<i>TABLE 42 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN</i>	91
Market Analysis of Solid Tumors by Type of Antibody Used in Treatment	93
Market Overview	93
Market Revenue	93
<i>TABLE 43 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	94
<i>FIGURE 19 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY TYPE, 2012-2019 (\$ MILLIONS)</i>	94
Market Analysis of Solid Tumors by Region	94
Market Overview	95
Market Revenue	95
<i>TABLE 44 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	96
<i>FIGURE 20 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY REGION, 2012-2019 (\$ MILLIONS)</i>	96
LYMPHOMAS AND LEUKEMIA	97
Lymphoma	97
<i>TABLE 45 TYPES OF LYMPHOMAS</i>	97
Leukemia	98
<i>TABLE 46 TYPES OF LEUKEMIA</i>	98
Market Analysis of Lymphomas and Leukemia by Type of Antibody Used in Treatment	99
Market Overview	99
Market Revenue	99
<i>TABLE 47 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	100
<i>FIGURE 21 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY TYPE, 2012-2019 (\$ MILLIONS)</i>	100
Market Analysis of Lymphomas and Leukemia by Region	101
Market Overview	101
Market Revenue	102
<i>TABLE 48 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	103
<i>FIGURE 22 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY REGION, 2012-2019 (\$ MILLIONS)</i>	103
OTHERS	103
Osteoporosis	104
Asthma	104
Age-related Macular Degeneration	104
Paroxysmal Nocturnal Hemoglobinuria	104
Cardiovascular Diseases	104
Respiratory Syncytial Virus Infection	105
Market Analysis of Other Diseases by Type of Antibody Used in Treatment	105
Market Overview	105
Market Revenue	106
<i>TABLE 49 GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	106

TOPIC	PAGE NO.
<i>FIGURE 23 GLOBAL REVENUE OF ANTIBODY DRUGS BY APPLICATION IN OTHER DISEASES BY TYPE, 2012-2019 (\$ MILLIONS)</i>	106
Market Analysis of Other Diseases by Region	107
Market Overview	107
Market Revenue	108
<i>TABLE 50 GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	108
<i>FIGURE 24 GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY REGION, 2012-2019 (\$ MILLIONS)</i>	108
CHAPTER 8 INDUSTRY STRUCTURE	111
MURINE MONOCLONAL ANTIBODIES	111
MARKET LEADERS	111
<i>TABLE 51 LEADING MANUFACTURERS/SUPPLIERS OF MURINE MONOCLONAL ANTIBODIES, 2013</i>	111
MARKET SHARE	111
<i>TABLE 52 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR MURINE MONOCLONAL ANTIBODIES, 2013 (%)</i>	112
<i>FIGURE 25 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR MURINE MONOCLONAL ANTIBODIES, 2013 (%)</i>	112
CHIMERIC MONOCLONAL ANTIBODIES	112
MARKET LEADERS	112
<i>TABLE 53 LEADING MANUFACTURERS/SUPPLIERS OF CHIMERIC MONOCLONAL ANTIBODIES, 2013</i>	113
MARKET SHARE	113
<i>TABLE 54 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR CHIMERIC MONOCLONAL ANTIBODIES, 2013 (%)</i>	113
<i>FIGURE 26 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR CHIMERIC MONOCLONAL ANTIBODIES, 2013 (%)</i>	113
HUMANIZED MONOCLONAL ANTIBODIES	114
MARKET LEADERS	114
<i>TABLE 55 LEADING MANUFACTURERS/SUPPLIERS OF HUMANIZED MONOCLONAL ANTIBODIES, 2013</i>	114
MARKET SHARE	115
<i>TABLE 56 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMANIZED MONOCLONAL ANTIBODIES, 2013 (%)</i>	115
<i>FIGURE 27 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMANIZED MONOCLONAL ANTIBODIES, 2013 (%)</i>	115
HUMAN MONOCLONAL ANTIBODIES	116
MARKET LEADERS	116
<i>TABLE 57 LEADING MANUFACTURERS/SUPPLIERS OF HUMAN MONOCLONAL ANTIBODIES, 2013</i>	116
MARKET SHARE	117
<i>TABLE 58 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMAN MONOCLONAL ANTIBODIES, 2013 (%)</i>	117
<i>FIGURE 28 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMAN MONOCLONAL ANTIBODIES, 2013 (%)</i>	118
CHAPTER 9 PATENT ANALYSIS	120
PATENTS BY YEAR	120

TOPIC	PAGE NO.
<i>TABLE 59 NUMBER OF PATENTS BY YEAR, 2009-JUNE 2014</i>	121
<i>FIGURE 29 NUMBER OF PATENTS BY YEAR, 2009-JUNE 2014</i>	121
PATENTS BY TYPE/CATEGORY	121
<i>TABLE 60 NUMBER OF PATENTS BY CATEGORY, 2009-JUNE 2014</i>	122
<i>FIGURE 30 NUMBER OF PATENTS BY CATEGORY, 2009-JUNE 2014</i>	122
PATENTS BY COMPANY	122
<i>TABLE 61 NUMBER OF PATENTS BY COMPANY, 2009-JUNE 2014</i>	123
PATENTS BY COUNTRY	125
<i>TABLE 62 NUMBER OF PATENTS BY COUNTRY, 2009-JUNE 2014</i>	125
<i>TABLE 63 PATENT SHARES BY COUNTRY, 2009-JUNE 2014</i>	126
<i>FIGURE 31 NUMBER OF PATENTS BY COUNTRY, 2009-JUNE 2014 (%) (%)</i>	126
PATENTS BY ASSIGNEE	127
<i>TABLE 64 NUMBER OF PATENTS BY ASSIGNEE, 2009-JUNE 2014</i>	127
<i>FIGURE 32 NUMBER OF PATENTS BY ASSIGNEE, 2009-JUNE 2014</i>	127
CHAPTER 10 CURRENT SITUATION	130
TECHNICAL ISSUES	130
THE HUMAN ANTIMOUSE ANTIBODY PROBLEM	130
Effects of the HAMA Response	130
Resolution of the HAMA Problem	131
ADVANTAGES OF HUMANIZED OR CHIMERIC OR TRANSGENIC ANTIBODIES	132
NEW TECHNOLOGIES IN ANTIBODY DEVELOPMENT	132
FUSION PROTEINS	132
AFFIBODIES	133
NANOBODIES	134
<i>TABLE 65 NANOBODIES IN DEVELOPMENT</i>	134
OTHER ADVANCES IN ANTIBODIES DEPENDING ON THE TREATMENT	134
FACTORS AFFECTING THE MONOCLONAL ANTIBODY DRUG MARKET	135
INCREASING PREVALENCE OF CHRONIC DISEASES	135
GROWING AGING POPULATION	135
LIFESTYLE CHANGES	135
NEW PRODUCT LAUNCHES	135
ADVANCEMENTS IN MANUFACTURING TECHNOLOGIES	136
PRICE CONTROLS	136
REGULATORY PRESSURES	136
ENTRY OF BIOLOGICS/BIOSIMILARS	137
LICENSING AGREEMENTS	137
MERGERS AND ACQUISITIONS	138
CHAPTER 11 COMPANY PROFILES	140
ABBOTT LABORATORIES	140
ALEXION PHARMACEUTICALS	140
AMGEN	141
BIOGEN IDEC	141
BRISTOL-MYERS SQUIBB	142
ELI LILLY AND CO.	143
GLAXOSMITHKLINE	144

TOPIC	PAGE NO.
HOFFMAN-LA ROCHE	144
JOHNSON & JOHNSON	145
MERCK & CO.	146
MERCK KGAA	147
NOVARTIS	148
SEATTLE GENETICS INC.	148
SPECTRUM PHARMACEUTICALS	149
TAKEDA PHARMACEUTICAL U.S.A. INC.	149
UCB COMPANY	150
CHAPTER 12 APPENDIX ABBREVIATIONS	152

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR ANTIBODY DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)	8
TABLE 1 EVOLUTION OF MONOCLONAL ANTIBODIES	11
TABLE 2 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES	12
TABLE 3 DIFFERENCES BETWEEN MONOCLONAL ANTIBODY DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS	12
TABLE 4 MURINE MONOCLONAL ANTIBODIES	14
TABLE 5 CHIMERIC MONOCLONAL ANTIBODIES	14
TABLE 6 HUMANIZED MONOCLONAL ANTIBODIES	15
TABLE 7 HUMAN MONOCLONAL ANTIBODIES	16
TABLE 8 DIFFERENCES BETWEEN HYBRIDOMA TECHNOLOGY AND RECOMBINANT TECHNOLOGY	18
TABLE 9 COMPARISON OF VARIOUS EXPRESSION SYSTEMS FOR RECOMBINANT PHARMACEUTICAL PROTEINS	21
TABLE 10 MURINE MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS	22
TABLE 11 CHIMERIC MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS	22
TABLE 12 HUMAN MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS	23
TABLE 13 HUMANIZED MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS	23
TABLE 14 NEW APPROVALS OF MONOCLONAL ANTIBODIES FROM JANUARY 2009 TO MAY 2014	26
TABLE 15 RECALLS FROM JANUARY 2009 TO JUNE 2014	29
TABLE 16 NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS FROM JANUARY 2009 TO JANUARY 2014	30
TABLE 17 SAFETY ALERTS FROM 2010 TO MAY 2014	31
TABLE 18 MONOCLONAL ANTIBODIES IN PHASE I CLINICAL TRIALS	35
TABLE 19 MONOCLONAL ANTIBODIES IN PHASE II CLINICAL TRIALS	39
TABLE 20 MONOCLONAL ANTIBODIES IN PHASE III CLINICAL TRIALS	43
TABLE 21 MONOCLONAL ANTIBODIES IN PHASE IV CLINICAL TRIALS	45
TABLE 22 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES FROM 2009 TO JUNE 2014	46
TABLE 23 GLOBAL REVENUE OF ANTIBODY DRUGS BY TYPE, THROUGH 2019 (\$ MILLIONS)	54
TABLE 24 MARKET SHARE OF ANTIBODY DRUGS BY TYPE, 2013 (%)	55
TABLE 25 GLOBAL REVENUE OF ANTIBODY DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)	58
TABLE 26 MARKET SHARE OF ANTIBODY DRUGS BY REGION, 2013 (%)	59
TABLE 27 GLOBAL REVENUE OF MURINE MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 (\$ MILLIONS)	61
TABLE 28 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 (\$ MILLIONS)	63
TABLE 29 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 (\$ MILLIONS)	66
TABLE 30 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 (\$ MILLIONS)	68
TABLE 31 GLOBAL REVENUE OF MANUFACTURING PROCESSES BY TYPE OF MONOCLONAL ANTIBODIES, THROUGH 2019 (\$ MILLIONS)	70
TABLE 32 MARKET SHARE OF ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2013 (%)	71
TABLE 33 GLOBAL REVENUE OF MURINE ANTIBODY DRUGS BY MANUFACTURING PROCESS, THROUGH 2019 (\$ MILLIONS)	73

TABLE HEADING	PAGE NO.
TABLE 34 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019 (\$ MILLIONS)	75
TABLE 35 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019 (\$ MILLIONS)	77
TABLE 36 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019 (\$ MILLIONS)	79
TABLE 37 GLOBAL REVENUE FOR ANTIBODY DRUGS BY DISEASES, THROUGH 2019 (\$ MILLIONS)	83
TABLE 38 MARKET SHARES FOR ANTIBODY DRUGS BY DISEASES, 2013 (%)	84
TABLE 39 VARIOUS TYPES OF AUTOIMMUNE DISEASES	85
TABLE 40 GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY TYPE, THROUGH 2019 (\$ MILLIONS)	88
TABLE 41 GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY REGION, THROUGH 2019 (\$ MILLIONS)	90
TABLE 42 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN	91
TABLE 43 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY TYPE, THROUGH 2019 (\$ MILLIONS)	94
TABLE 44 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY REGION, THROUGH 2019 (\$ MILLIONS)	96
TABLE 45 TYPES OF LYMPHOMAS	97
TABLE 46 TYPES OF LEUKEMIA	98
TABLE 47 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY TYPE, THROUGH 2019 (\$ MILLIONS)	100
TABLE 48 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY REGION, THROUGH 2019 (\$ MILLIONS)	103
TABLE 49 GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY TYPE, THROUGH 2019 (\$ MILLIONS)	106
TABLE 50 GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY REGION, THROUGH 2019 (\$ MILLIONS)	108
TABLE 51 LEADING MANUFACTURERS/SUPPLIERS OF MURINE MONOCLONAL ANTIBODIES, 2013	111
TABLE 52 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR MURINE MONOCLONAL ANTIBODIES, 2013 (%)	112
TABLE 53 LEADING MANUFACTURERS/SUPPLIERS OF CHIMERIC MONOCLONAL ANTIBODIES, 2013	113
TABLE 54 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR CHIMERIC MONOCLONAL ANTIBODIES, 2013 (%)	113
TABLE 55 LEADING MANUFACTURERS/SUPPLIERS OF HUMANIZED MONOCLONAL ANTIBODIES, 2013	114
TABLE 56 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMANIZED MONOCLONAL ANTIBODIES, 2013 (%)	115
TABLE 57 LEADING MANUFACTURERS/SUPPLIERS OF HUMAN MONOCLONAL ANTIBODIES, 2013	116
TABLE 58 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMAN MONOCLONAL ANTIBODIES, 2013 (%)	117
TABLE 59 NUMBER OF PATENTS BY YEAR, 2009-JUNE 2014	121
TABLE 60 NUMBER OF PATENTS BY CATEGORY, 2009-JUNE 2014	122
TABLE 61 NUMBER OF PATENTS BY COMPANY, 2009-JUNE 2014	123
TABLE 62 NUMBER OF PATENTS BY COUNTRY, 2009-JUNE 2014	125
TABLE 63 PATENT SHARES BY COUNTRY, 2009-JUNE 2014	126
TABLE 64 NUMBER OF PATENTS BY ASSIGNEE, 2009-JUNE 2014	127

TABLE HEADING	PAGE NO.
TABLE 65 NANOBODIES IN DEVELOPMENT	134

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR ANTIBODY DRUGS BY REGION, 2012-2019 (\$ MILLIONS)	8
FIGURE 1 GLOBAL REVENUE OF ANTIBODY DRUGS BY TYPE, 2012-2019 (\$ MILLIONS)	55
FIGURE 2 MARKET SHARE OF ANTIBODY DRUGS BY TYPE, 2013 (%)	55
FIGURE 3 GLOBAL REVENUE OF ANTIBODY DRUGS BY REGION, 2012-2019 (\$ MILLIONS)	58
FIGURE 4 MARKET SHARE OF ANTIBODY DRUGS BY REGION, 2013 (%)	59
FIGURE 5 GLOBAL REVENUE OF MURINE MONOCLONAL ANTIBODIES BY REGION, 2012-2019 (\$ MILLIONS)	61
FIGURE 6 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY REGION, 2012-2019 (\$ MILLIONS)	63
FIGURE 7 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY REGION, 2012-2019 (\$ MILLIONS)	66
FIGURE 8 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY REGION, 2012-2019 (\$ MILLIONS)	69
FIGURE 9 GLOBAL REVENUE OF MANUFACTURING PROCESSES BY TYPE OF MONOCLONAL ANTIBODIES, 2012-2019 (\$ MILLIONS)	70
FIGURE 10 MARKET SHARE OF ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2013 (%)	71
FIGURE 11 GLOBAL REVENUE OF MURINE ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2012-2019 (\$ MILLIONS)	73
FIGURE 12 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019 (\$ MILLIONS)	75
FIGURE 13 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019 (\$ MILLIONS)	77
FIGURE 14 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019 (\$ MILLIONS)	79
FIGURE 15 GLOBAL REVENUE FOR ANTIBODY DRUGS BY DISEASES, 2012-2019 (\$ MILLIONS)	83
FIGURE 16 MARKET SHARE FOR ANTIBODY DRUGS BY DISEASES, 2013 (%)	84
FIGURE 17 GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY TYPE, 2012-2019 (\$ MILLIONS)	88
FIGURE 18 GLOBAL MARKET FOR ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY REGION, 2012-2019 (\$ MILLIONS)	90
FIGURE 19 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY TYPE, 2012-2019 (\$ MILLIONS)	94
FIGURE 20 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY REGION, 2012-2019 (\$ MILLIONS)	96
FIGURE 21 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY TYPE, 2012-2019 (\$ MILLIONS)	100
FIGURE 22 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY REGION, 2012-2019 (\$ MILLIONS)	103
FIGURE 23 GLOBAL REVENUE OF ANTIBODY DRUGS BY APPLICATION IN OTHER DISEASES BY TYPE, 2012-2019 (\$ MILLIONS)	106
FIGURE 24 GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY REGION, 2012-2019 (\$ MILLIONS)	108
FIGURE 25 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR MURINE MONOCLONAL ANTIBODIES, 2013 (%)	112
FIGURE 26 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR CHIMERIC MONOCLONAL ANTIBODIES, 2013 (%)	113

FIGURE TITLE	PAGE NO.
FIGURE 27 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMANIZED MONOCLONAL ANTIBODIES, 2013 (%)	115
FIGURE 28 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMAN MONOCLONAL ANTIBODIES, 2013 (%)	118
FIGURE 29 NUMBER OF PATENTS BY YEAR, 2009-JUNE 2014	121
FIGURE 30 NUMBER OF PATENTS BY CATEGORY, 2009-JUNE 2014	122
FIGURE 31 NUMBER OF PATENTS BY COUNTRY, 2009-JUNE 2014 (%) (%)	126
FIGURE 32 NUMBER OF PATENTS BY ASSIGNEE, 2009-JUNE 2014	127